|
[1]European Association for Study of Liver.EASL recommendations on treatment of hepatitis C 2015[J].J Hepatol, 2015, 63 (1) :199-236.
|
|
[2]WEI L, LOK AS.Impact of new hepatitis C treatments in different regions of the world[J].Gastroenterology, 2014, 146 (5) :1145-1150.
|
|
[3]YONGHAO G, JIN X, JUN L, et al.An epidemiological serosurvey of hepatitis B virus shows evidence of declining prevalence due to hepatitis B vaccination in central China[J].Int J Infect Dis, 2015, 40:75-80.
|
|
[4]SAGNELLI E, COPPOLA N, PISATURO M, et al.HBV superinfection in HCV chronic carriers:a disease that is frequently severe but associated with the eradication of HCV[J].Hepatology, 2009, 49 (4) :1090-1097.
|
|
[5]KONSTANTINOU D, DEUTSCH M.The spectrum of HBV/HCV coinfection:epidemiology, clinical characteristics, viralinteractions and management[J].Ann Gastroenterol, 2015, 28 (2) :221-228.
|
|
[6]YU G, CHI X, WU R, et al.Replication inhibition of hepatitis B virus and hepatitis C virus in co-infected patients in Chinese population[J].PLo S One, 2015, 10 (9) :e0139015.
|
|
[7]WANG C, JI D, CHEN J, et al.Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents[J].Clin Gastroenterol Hepatol, 2017, 15 (1) :132-136.
|
|
[8]WU JC, CHEN CL, HOU MC, et al.Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B:application and limitations of the polymerase chain reaction[J].Hepatology, 1994, 19 (4) :836-840.
|
|
[9]PONTISSO P, RUVOLETTO MG, FATTOVICH G, et al.Clinical and virological profiles in patients with multiple hepatitis virus infections[J].Gastroenterology, 1993, 105 (5) :1529-1533.
|
|
[10]CHU CM, SHEEN IS, LIAW YF.The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B[J].Gastroenterology, 1994, 107 (1) :189-195.
|
|
[11]RAIMONDO G, ALLAIN JP, BRUNETTO MR, et al.Statements from the Taormina expert meeting on occult hepatitis B virus infection[J].J Hepatol, 2008, 49 (4) :652-657.
|
|
[12]CACCIOLA I, POLLICINO T, SQUADRITO G, et al.Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease[J].N Engl J Med, 1999, 341 (1) :22-26.
|
|
[13]CHO LY, YANG JJ, KO KP, et al.Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma:systematic review and meta-analysis[J].Int J Cancer, 2011, 128 (1) :176-184.
|
|
[14]OH JK, SHIN HR, LIM MK, et al.Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area:a community-based cohort study[J].BMC Cancer, 2012, 12:452.
|
|
[15]FONG TL, Di BISCEGLIE AM, WAGGONER JG, et al.The significance of antibody to hepatitis C virus in patients with chronic hepatitis B[J].Hepatology, 1991, 14 (1) :64-67.
|
|
[16]DONATO F, BOFFETTA P, PUOTI M.A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma[J].Int J Cancer, 1998, 75 (3) :347-354.
|
|
[17]CHIARAMONTE M, STROFFOLINI T, VIAN A, et al.Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis[J].Cancer, 1999, 85 (10) :2132-2137.
|
|
[18]di BISCEGLIE AM, LOK AS, MARTIN P, et al.Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs:just the tip of the iceberg?[J].Hepatology, 2015, 61 (2) :703-711.
|
|
[19]HWANG JP, LOK AS.Management of patients with hepatitis B who require immunosuppressive therapy[J].Nat Rev Gastroenterol Hepatol, 2014, 11 (4) :209-219.
|
|
[20]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.
|
|
[21]CHEN G, WANG C, CHEN J, et al.Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents:a systematic review and meta-analysis[J].Hepatology, 2017.[Epub ahead of print]
|
|
[22]COLLINS JM, RAPHAEL KL, TERRY C, et al.Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir[J].Clin Infect Dis, 2015, 61 (8) :1304-1306.
|
|
[23]ENDE AR, KIM NH, YEH MM, et al.Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir:a case report[J].J Med Case Rep, 2015, 9:164.
|
|
[24]TAKAYAMA H, SATO T, IKEDA F, et al.Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection[J].Hepatol Res, 2016, 46 (5) :489-491.
|
|
[25]HAYASHI K, ISHIGAMI M, ISHIZU Y, et al.A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy:hepatitis B virus reactivation or acute self-limited hepatitis?[J].Clin J Gastroenterol, 2016, 9 (4) :252-256.
|
|
[26]de MONTE A, COURJON J, ANTY R, et al.Direct-acting antiviral treatment in adults infected with hepatitis C virus:reactivation of hepatitis B virus coinfection as a further challenge[J].J Clin Virol, 2016, 78:27-30.
|
|
[27]PILLAI AA, WEDD J, NORVELL JP, et al.Simeprevir and sofosbuvir (SMV-SOF) for 12 weeks for the treatment of chronic hepatitis C genotype 1 infection:a real world (transplant) hepatology practice experience[J].Am J Gastroenterol, 2016, 111 (2) :250-260.
|
|
[28]GANE EJ, HYLAND RH, AN D, et al.Ledipasvir and sofosbuvir for HCV-infection in patients coinfected with HBV[J].Antivir Ther, 2016, 21 (7) :605-609.
|
|
[29]U.S.Food and Drug Adminstration.FDA Drug Safety Communication:FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C[EB/OL].[2016-10-4].https://www.fda.gov/Drugs/Drug Safety/ucm 522932.htm.
|
|
[30]YAN LB, RAO HY, MA YJ, et al.Hepatitis B virus infection in Chinese patients with hepatitis C virus infection:prevalence, clinical characteristics, viral interactions and host genotypes:a nationwide cross-sectional study[J].BMJ Open, 2016, 6 (10) :e012016.
|
|
[31]BERSOFF-MATCHA SJ, CAO K, JASON M, et al.Hepatitis B Virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus:a review of cases reported to the U.S.food and drug administration adverse event reporting system[J].Ann Intern Med, 2017.[Epub ahead of print]
|
|
[32]LAU GK, YIU HH, FONG DY, et al.Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy[J].Gastroenterology, 2003, 125 (6) :1742-1749.
|
|
[33]European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2016[J].J Hepatol, 2017, 66 (1) :153-194.
|
|
[34]European Association for the Study of the Liver.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J].J Hepatol, 2017.[Epub ahead of print]
|
|
[35]OMATA M, KANDA T, WEI L, et al.APASL consensus statements and recommendation on treatment of hepatitis C[J].Hepatol Int, 2016, 10 (5) :702-726.
|
|
[36]SARIN SK, KUMAR M, LAU GK, et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update[J].Hepatol Int, 2016, 10 (1) :1-98.
|
|
[37]AASLD IDSA HCV Guidance panel.Recommendations for testing, managing, and treating hepatitis C[J/OL].http://www.hcvguidelines.org/full-report/monitoring-patients-who-are-startinghepatitis-c-treatment-are-treatment-or-have.
|
DownLoad: